Details for New Drug Application (NDA): 215718
✉ Email this page to a colleague
NDA 215718 describes DAPSONE, which is a drug marketed by Alembic, Amneal, Cosette, Encube, Mylan, Padagis Israel, Taro, Torrent, Trupharma, Zydus Lifesciences, Actavis Llc, Alvogen, Chartwell Rx, Everest Life Sci, Nostrum Labs Inc, Novitium Pharma, and Rising, and is included in twenty-three NDAs. It is available from twenty-four suppliers. Additional details are available on the DAPSONE profile page.
The generic ingredient in DAPSONE is dapsone. There are eight drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the dapsone profile page.
The generic ingredient in DAPSONE is dapsone. There are eight drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the dapsone profile page.
Suppliers and Packaging for NDA: 215718
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| DAPSONE | dapsone | GEL;TOPICAL | 215718 | ANDA | Alembic Pharmaceuticals Inc. | 62332-663 | 62332-663-30 | 1 BOTTLE, PUMP in 1 CARTON (62332-663-30) / 30 g in 1 BOTTLE, PUMP |
| DAPSONE | dapsone | GEL;TOPICAL | 215718 | ANDA | Alembic Pharmaceuticals Inc. | 62332-663 | 62332-663-60 | 1 BOTTLE, PUMP in 1 CARTON (62332-663-60) / 60 g in 1 BOTTLE, PUMP |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | GEL;TOPICAL | Strength | 7.5% | ||||
| Approval Date: | Oct 27, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
